| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8952064 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US9089534 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US8367102 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US9078925 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
| US7435427 | SUN PHARM INDS INC | Pharmaceutical semi-solid composition of isotretinoin |
Sep, 2021
(2 years ago) | |
Absorica is owned by Sun Pharm Inds Inc.
Absorica contains Isotretinoin.
Absorica has a total of 5 drug patents out of which 5 drug patents have expired.
Expired drug patents of Absorica are:
- US8952064
- US9089534
- US8367102
- US9078925
- US7435427
Absorica was authorised for market use on 25 May, 2012.
Absorica is available in capsule;oral dosage forms.
Absorica can be used as treatment of a skin disorder.
The generics of Absorica are possible to be released after 21 September, 2021.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 25, 2015 |
Drugs and Companies using ISOTRETINOIN ingredient
Market Authorisation Date: 25 May, 2012
Treatment: Treatment of a skin disorder
Dosage: CAPSULE;ORAL
How can I launch a generic of ABSORICA before it's drug patent expiration?
More Information on Dosage
ABSORICA family patents
